These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36857008)

  • 1. A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in men with obesity.
    De Herdt C; De Block C; Francque S; Verrijken A; Van Dessel K; Van Gaal L; Van Cauwenberghe J; Dirinck E
    Endocrine; 2023 Apr; 80(1):54-63. PubMed ID: 36857008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
    Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
    Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD.
    Sarkar MA; Suzuki A; Abdelmalek MF; Yates KP; Wilson LA; Bass NM; Gill R; Cedars M; Terrault N;
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1267-1274.e1. PubMed ID: 33010412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
    Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
    Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologically proven hepatic steatosis associates with lower testosterone levels in men with obesity.
    Van de Velde F; Bekaert M; Hoorens A; Geerts A; T'Sjoen G; Fiers T; Kaufman JM; Van Nieuwenhove Y; Lapauw B
    Asian J Androl; 2020; 22(3):252-257. PubMed ID: 31274482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvesicular Steatosis in Individuals with Obesity: a Histological Marker of Non-alcoholic Fatty Liver Disease Severity.
    Germano CW; Mega PF; Mattosinho TJAP; Dias LLC; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
    Obes Surg; 2023 Mar; 33(3):813-820. PubMed ID: 36694089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Li G; Rios RS; Wang XX; Yu Y; Zheng KI; Huang OY; Tang LJ; Ma HL; Jin Y; Targher G; Byrne CD; Pan XY; Zheng MH
    Br J Nutr; 2022 Jun; 127(11):1613-1620. PubMed ID: 34176541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
    Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
    Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
    AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.